Metabolic PET/CT Imaging in Thyroid Cancer

  • Ioan PrataEmail author
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


Please provide affiliation details for the corresponding author.


  1. 1.
    Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol. 2002;37:169–74.CrossRefPubMedGoogle Scholar
  2. 2.
    Treglia G, Giovanella L, Rufini V. PET and PET/CT imaging in thyroid and adrenal diseases: an update. Hormones (Athens). 2013;12(3):327–33.Google Scholar
  3. 3.
    Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37(9):1468–72.PubMedGoogle Scholar
  4. 4.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1189.Google Scholar
  5. 5.
    Wang N, Zhai H, Yingli L. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J Otolaryngol Head Neck Surg. 2013;42:38.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012;97:3866–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Frey P, Townsend D, Jeavons A, Donath A. In vivo imaging of the human thyroid with a positron camera using I-124. Eur J Nucl Med. 1985;10(9-10):472–6.PubMedGoogle Scholar
  8. 8.
    Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Phan HT, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:958–65.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun. 2001;22:485–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28(1):64–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Ambrosini V, Rubello D, Nanni C, Al-Nahhas A, Fanti S. 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun. 2008;29(5):415–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013;34(11):1084–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Sturgeon C, Angelos P. Identification and treatment of aggressive thyroid cancers. Oncology (Williston Park). 2006;20(3):253–60.Google Scholar
  15. 15.
    Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(2):121–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga JR. F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan. Rev Esp Med Nucl. 2005;24(1):5–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, An GI, Choi TH, Cheon GJ, Soh EY, Chung WY. Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma. J Korean Med Sci. 2012;27(9):1019–26.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Buscombe JR. Radionuclides in the management of thyroid cancer. Cancer Imaging. 2007;7:202–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Verbeek HH, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53(12):1863–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Kauhanen S, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Bradford Teaching Hospitals NHS Foundation TrustBradfordUK

Personalised recommendations